Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
174 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06773910 | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)(TIGOS-LS) | active not recruiting | Phase 2 | 250 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma(CORE-MM) | recruiting | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER |
| 1 |
| Sep 4, 2026 |
| clinicaltrials |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)(FRUITFUL) | recruiting | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06974786 | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma(FASTER) | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04699630 | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer | completed | Phase 2 | 121 | SCRI Development Innovations, LLCOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05748834 | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | recruiting | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02195011 | Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases | completed | Phase 2 | 26 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02356822 | Sarah Cannon Outcomes Registry | withdrawn | — | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | terminated | Phase 1 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | terminated | Phase 2 | 6 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02887248 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | terminated | Phase 2 | 3 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03436862 | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04209725 | A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | terminated | Phase 2 | 1 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT02317991 | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | completed | Phase 2 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | completed | Phase 2 | 71 | SCRI Development Innovations, LLCOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT00392821 | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT00456261 | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC | completed | Phase 2 | 110 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT01033032 | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT01154335 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 | 18 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT00600015 | Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 166 | SCRI Development Innovations, LLCOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01226732 | A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors | completed | Phase 1 | 23 | SCRI Development Innovations, LLCOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT00193414 | Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 72 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00193427 | Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 75 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00193479 | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00393068 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00545766 | Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT00741988 | Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 82 | SCRI Development Innovations, LLCOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT00308516 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | completed | Phase 2 | 66 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT00805961 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | completed | Phase 2 | 68 | SCRI Development Innovations, LLCOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | terminated | Phase 2 | 4 | SCRI Development Innovations, LLCOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT00193128 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | completed | Phase 1 / Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00591734 | RAD001 Plus Bevacizumab in Metastatic Melanoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00629499 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | completed | Phase 2 | 63 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00193206 | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | completed | Phase 2 | 123 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT00866905 | Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer | completed | Phase 2 | 168 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT00405938 | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer | completed | Phase 2 | 79 | SCRI Development Innovations, LLCOTHER | 1 | Nov 18, 2021 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials